European CHMP issues positive opinion for Atripla.
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002170:Canada; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017277:Drug Approval; D004338:Drug Combinations; D000068257:Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D005060:Europe; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D063065:Organophosphonates / Q000627:therapeutic use*; D010078:Oxazines / Q000627:therapeutic use*; D014481:United States
D019380:Anti-HIV Agents; D004338:Drug Combinations; D000068257:Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D063065:Organophosphonates; D010078:Oxazines; D003841:Deoxycytidine; D000225:Adenine